<?xml version="1.0" encoding="UTF-8"?><urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:image="http://www.google.com/schemas/sitemap-image/1.1"><url><loc>https://insights.citeline.com/pink-sheet/market-access/health-technology-assessment/worrisome-bill-could-worsen-brazils-hta-landscape-say-critics-YO6GP6VG5RDD7KFGBICHIUSCRQ/</loc><lastmod>2026-04-15T23:33:29.887Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/39V78zkR4oogwKzTYU5aVZ61L8M=/cloudfront-us-east-1.images.arcpublishing.com/norstella/BZGVSCSK3VDCPC2RK6H2B535NQ.jpg</image:loc><image:caption><![CDATA[Proposed changes to Brazil's HTA system would make the system less predictable for pharmaceutical companies, say critics.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/pathways-and-standards/review-pathways/could-structured-not-ad-hoc-us-fda-flexibility-increase-rare-disease-development-certainty-BYXJENIJLFEINOSO72RS53ZJHE/</loc><lastmod>2026-04-15T23:33:25.93Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/GVeDyeg8IjPmnlR5k3tQsNraLDo=/cloudfront-us-east-1.images.arcpublishing.com/norstella/H65KIT3CVBC7POKLO2PHTOB32E.jpg</image:loc><image:caption><![CDATA[The Haystack Project called for the FDA to clarify a route for rare disease flexibility instead of handling it case by case.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/legislation/eu-pharma-legislation-reform/new-eu-market-exclusivity-rules-set-high-threshold-lawyer-says-EVI2EHI4AFGWXHYL5I75BAAVVM/</loc><lastmod>2026-04-15T23:32:40.904Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/yRP_JART0042yRz9WDIIEJabad8=/cloudfront-us-east-1.images.arcpublishing.com/norstella/JZ6JSIUH6JAHHJD2ZMSRNG4WIM.jpg</image:loc><image:caption><![CDATA[The EU pharma package introduces some uncertainty for developers, a lawyer says]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/policy-regulation/us-fda-peptide-review-signals-policy-shift-but-manufacturing-regulatory-hurdles-persist-RSOAIYFYV5E4LH5XY5JUZAL2GU/</loc><lastmod>2026-04-15T23:32:22.089Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/1sVJPYy7bHdNmizVFYfZx4iKofE=/cloudfront-us-east-1.images.arcpublishing.com/norstella/SG4GWQQZJBGGXDIE3DLYV4MXMU.jpg</image:loc><image:caption><![CDATA[An FDA advisory committee will consider lifting restrictions on some peptides after the agency restricted them in 2023.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/medtech-insight/device-area/womens-health/osteoboost-raises-8m-to-scale-fda-cleared-vibration-device-for-osteopenia-6AOIRBNZIREU7LOWUCOCWLVRTU/</loc><lastmod>2026-04-15T22:01:40.294Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/yF5rV5Xwj1AaPm-kDRwuEb0SOiU=/cloudfront-us-east-1.images.arcpublishing.com/norstella/KEP64DOW45FJ3DI45PZ7J4GNFE.jpg</image:loc><image:caption><![CDATA[Osteoboost raised $8m in series A-prime funding, which will be used to expand production and sales of its FDA-cleared wearable vibration therapy for osteopenia.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/hbw-insight/wellness/business/deals/unilever-continues-growing-nutrition-portfolio-by-acquiring-gruns-greens-supplement-firm-OGC5EYGMNJGO7AIZYGHRKSWI5U/</loc><lastmod>2026-04-15T21:46:31.109Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/pXusk_sFvHqsEklqiteOw-TCPwI=/cloudfront-us-east-1.images.arcpublishing.com/norstella/67KO3YFISZEAZIDKORPZ3WQWNQ.jpg</image:loc><image:caption><![CDATA[Grüns original product, a daily nutrient support gummy, contains more than 30 organic fruits and vegetables, 21 vitamins and minerals and 6g prebiotic fiber.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/medtech-insight/conferences/lsx/lsx-panel-takes-on-present-and-future-of-neurotech-B52MZRJ6CJAP3HGO6V6BVK3CU4/</loc><lastmod>2026-04-15T21:21:25.199Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/y5twV3N6mOAlJ67xMuygkzbYq-E=/cloudfront-us-east-1.images.arcpublishing.com/norstella/QO2T54G6TBA3DHWL6SSWX5DVJM.jpg</image:loc><image:caption><![CDATA[Medtech Insight managing editor Marion Webb; INBRAIN CEO Carolina Aguilar; Features Capital managing partner Jenny Barba; and Synchron CCO Kurt Haggstrom participated in a Sept. 17 panel at LSX in Boston.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/business/start-ups-and-smes/biopharma-mid-cap-investors-on-a-yo-yo-diet-in-q1-BVJQ5BYFKZDJ5AEY52B6QEI6QE/</loc><lastmod>2026-04-15T20:15:59.698Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/y6pKB1j_wURfmQ3rHEcNPkfS4Tw=/cloudfront-us-east-1.images.arcpublishing.com/norstella/Z2KQ72KVCRFONKDUDCA4CPCVH4.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/scrip/therapeutic-category/immunological/bmsbain-300m-venture-emerges-as-beeline-with-lead-asset-nearing-pivotal-stage-SFEY2R3ONZGCLDER2SV73PTB7A/</loc><lastmod>2026-04-15T20:15:08.639Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/B7WPpa2ySE7fVWAAT5dRmJGmg6k=/cloudfront-us-east-1.images.arcpublishing.com/norstella/HNZCCIFMGNEYLLZH74SZVZGBU4.jpg</image:loc><image:caption><![CDATA[Beeline launches with programs in preclinical through Phase IIb ]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/leadership/interviews/poolbeg-well-placed-to-calm-the-cytokine-storm-2UNEWCF7NBFB5OYLE2HSSKSSK4/</loc><lastmod>2026-04-15T20:14:09.724Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/z2T2PG5stRflslUJ2R1WeWD4GBQ=/cloudfront-us-east-1.images.arcpublishing.com/norstella/6XI3CNVRUNHJ3GOWXAIRCUEYDQ.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/scrip/business/financing/revolutions-strong-data-garner-an-upsized-investor-response-7VI33EIWDBEKHKGYXXQ4XILH7I/</loc><lastmod>2026-04-15T20:13:20.905Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/eVF350J0i5S-Tj9lVyoLEag5UNw=/cloudfront-us-east-1.images.arcpublishing.com/norstella/OD65LKAB6FA6PBYJQFA5TJECZM.jpg</image:loc><image:caption><![CDATA[Biopharma valuations have surged on positive clinical catalysts]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/business/deals/jazz-talks-deals-amid-business-strategy-evolution-6CFWLLQ52BEIZGO6NGG6E5YTBY/</loc><lastmod>2026-04-15T20:12:47.362Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/OWdarYXuEUFyf_tgdaiagZjrDm0=/cloudfront-us-east-1.images.arcpublishing.com/norstella/W72S7LJOVJA3FHHDIL3SCQCDMQ.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/medtech-insight/business/strategy/cardiovascular-leads-jj-medtechs-q1-as-abiomed-and-shockwave-deliver-double-digit-growth-TNSK3DNVJRH6BAGJN3ALGYT7IM/</loc><lastmod>2026-04-15T18:40:56.004Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/gQGAEbTu6Xw_1G8VbPYa0FzmPNs=/cloudfront-us-east-1.images.arcpublishing.com/norstella/56LCTQSSIRBINOPJ5B6OBY6EN4.jpg</image:loc><image:caption><![CDATA[Cardiovascular was the division's strongest performer. Electrophysiology grew 9.5%, driven by newly launched products including VARIPULSE, J&J's pulsed field ablation platform for atrial fibrillation. Picture Courtesy: Shutterstock]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/medtech-insight/conferences/medcon/medcon-preview-mdufa-ai-qmsr-fda-inspections-on-tap-for-columbus-conference-HR24AUL2B5CORHLADYIL2YA4YY/</loc><lastmod>2026-04-15T18:37:35.956Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/NgS_Skx26yADReL8-yVNUqCcb80=/cloudfront-us-east-1.images.arcpublishing.com/norstella/IFKCOB2V5VBP7I7WMNLDSE6GSM.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/in-vivo/innovation/healthtech-start-ups-set-the-tone-at-biowales-26-KMHU6TMATFGEJDTOSUBLKI6V6E/</loc><lastmod>2026-04-15T16:37:41.744Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/htWootYgafgttueXYlGGUvQ75Ck=/cloudfront-us-east-1.images.arcpublishing.com/norstella/O7UKKLKOWRCPBPIUYAS4GI6JVA.jpg</image:loc><image:caption><![CDATA[Technologies made in Wales bid for funding]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/in-vivo/innovation/how-an-italian-ocular-aav-innovator-is-bucking-the-trend-in-gene-therapy-63OPEMWE5ZFPFDYCTUXVGHSRMU/</loc><lastmod>2026-04-15T16:30:43.383Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/l_N3I4WWePrM-fDJmkLYmiRVUtA=/cloudfront-us-east-1.images.arcpublishing.com/norstella/BL7SGYWNTJJRVM6J3WQ2LAOIY4.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/in-vivo/leadership/in-vivos-2026-rising-leaders-P65JE4EAZ5CDDAW4ABFKNABFKY/</loc><lastmod>2026-04-15T16:21:34.752Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/Bkq1T_WCg0g9lUN8trx1sIzkICE=/cloudfront-us-east-1.images.arcpublishing.com/norstella/6UBHVQ6UNVE6LL54ST7GOKUATI.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/hbw-insight/wellness/policy-and-regulation/legal/storm-of-interest-could-follow-ftc-complaint-alleging-false-income-claims-by-mlm-distributor-3JESEYP6XVB5HONE7K7AAXEHAI/</loc><lastmod>2026-04-15T15:44:19.738Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/XdjANw8uj-L_UTo6PG47Y0LKQEc=/cloudfront-us-east-1.images.arcpublishing.com/norstella/F4NYYZQ5F5AXRINHUS7VSPWCFE.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/generics-bulletin/leadership/frances-gemme-becomes-alma-TUVZUO2BKRC25KSUIZL6QYTUNQ/</loc><lastmod>2026-04-15T14:31:10.839Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/RXNoYPub99ssjC_87E0WlfAjuB4=/cloudfront-us-east-1.images.arcpublishing.com/norstella/Q4GK6NKNL5EHNMLECNKO5EGBNI.jpg</image:loc><image:caption><![CDATA[ALMA is the new name for the French generics and biosimilars association]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/generics-bulletin/legalandip/mankind-and-amneal-launch-us-lumigan-generics-despite-valid-patent-DT3DUZO62BEW7PLXUNQMRQ7PRA/</loc><lastmod>2026-04-15T14:00:26.504Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/q6Bwpn0uLEvUp1QQtFzHc68HrOk=/cloudfront-us-east-1.images.arcpublishing.com/norstella/T7ZRIAZOL5CQHGKIJTZFUTFR7I.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/hbw-insight/health/business/deals/lupin-acquires-visufarma-to-grow-otc-ophthalmology-offering-IPUH4EDF7JDT7CBQRQD7QQD6AA/</loc><lastmod>2026-04-15T13:44:17.853Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/AIviGC7eXnXF8foOj0e04m6ZAHk=/cloudfront-us-east-1.images.arcpublishing.com/norstella/J6HIJ445ARDWPIWM7VEZHTK72U.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/generics-bulletin/legalandip/samsung-win-protects-early-foothold-in-us-ustekinumab-market-AYRME42L5JDGNAMCHU7JZRJPYM/</loc><lastmod>2026-04-15T13:18:41.238Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/CYNJ-UqimTKeDy0RDnGSSglMA7c=/cloudfront-us-east-1.images.arcpublishing.com/norstella/GFVCGXWH7RDA5C5MQZETQDWLXA.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/medtech-insight/conferences/study-validates-ebenbuilds-lung-digital-twin-for-drug-intake-next-up-trials-for-clinical-use-KBTI5TTEZBAXXLTMJKC7NKLWLU/</loc><lastmod>2026-04-15T13:00:23.401Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/oX9GxW8AWdoi-vhAC5Hl-_AYNTU=/cloudfront-us-east-1.images.arcpublishing.com/norstella/RA7KHNCVJZGWNB67LVYLEHIYYU.png</image:loc><image:caption><![CDATA[Lung digital twin with aerosol particles using Ebenbuild's technology.]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/in-vivo/leadership/rising-leaders/rising-leaders-helping-ai-software-enter-healthcare-systems-and-markets-6XQQYKBKIRA6VDZIJDIL2K5FDI/</loc><lastmod>2026-04-15T12:58:06.506Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/wQVUNQbB4bEzwEzR5ZhC9B1rla0=/cloudfront-us-east-1.images.arcpublishing.com/norstella/CIEYX2OT2RDKRPZOTTRLJGVS4Q.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/in-vivo/leadership/rising-leaders/in-vivos-2026-rising-leaders-at-a-glance-2S7BIEWE4JD75JKTCLJY3KZXJU/</loc><lastmod>2026-04-15T12:54:31.029Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/qUL2KwheSy8OVGjzwegnRzV2440=/cloudfront-us-east-1.images.arcpublishing.com/norstella/UPM263F335AMNDWRUYECR4FGZI.png</image:loc></image:image></url><url><loc>https://insights.citeline.com/scrip/advanced-therapies/excipients-as-strategic-enablers-of-advanced-therapies-Y26T3MRBYBCIDHXU7IP2JYHVVE/</loc><lastmod>2026-04-15T11:11:32.926Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/QoiiO0SYsAQ8VfC5pudZRXPiPi8=/cloudfront-us-east-1.images.arcpublishing.com/norstella/KNEFMJLDCNEKLDYMER52PX5ME4.png</image:loc></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/legislation/why-india-is-considering-the-essential-commodities-act-for-pharma-amid-iran-war-E2K4C6TO7FEYHNUTQREDWYJSRI/</loc><lastmod>2026-04-15T11:05:27.234Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/TJtdgk40utzmVNfAaEEtBxxktRQ=/cloudfront-us-east-1.images.arcpublishing.com/norstella/YIGANQK24FFZNK5JKFOJEH7IVM.jpg</image:loc><image:caption><![CDATA[Indian Pharma Is Suffering Repercussions Of The US-Israel Coalition's Attack On Iran]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/business/supply-chain/amid-iran-war-india-tries-to-keep-lights-on-with-duty-cuts-PMW77UO2HZH4JEFN2ADJJ4PIZU/</loc><lastmod>2026-04-15T11:04:34.89Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/BegAK9cO331jGHha6kUvgqh8PDg=/cloudfront-us-east-1.images.arcpublishing.com/norstella/QAVEVFLU7BH3ZGD3F42E7X3HPE.jpg</image:loc><image:caption><![CDATA[Freight Rates, Input Costs Higher For Pharma Post Iran War]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/generics-bulletin/legalandip/court-keeps-core-copaxone-claims-alive-against-teva-XANT6E4QPRB2JOART7UCGNVEWM/</loc><lastmod>2026-04-15T11:03:53.557Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/AvkuALYtl3bnezvUlY6SjfcOCao=/cloudfront-us-east-1.images.arcpublishing.com/norstella/S32P4UU4TRGXPAAEL4S546TF5Y.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/pink-sheet/market-access/prolonged-iran-ports-blockade-risks-drug-shortages-wider-supply-chain-woes-OVV2Q5N5RBFARHDE44FPU6XK5A/</loc><lastmod>2026-04-15T11:02:29.241Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/t2uGrXbrImnkjA2XhokAhWNJiUY=/cloudfront-us-east-1.images.arcpublishing.com/norstella/7PWBKJNARRBJJGPSUZRTV5LACQ.jpg</image:loc><image:caption><![CDATA[Pharma's Supply Chain Woes Could Expand If Freight Disruptions Continue]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/business/deals/daiichi-sankyo-tightens-oncology-focus-through-otc-divestment-to-suntory-HSPKYD2BXJDYZI2IFN2NWBCZVY/</loc><lastmod>2026-04-15T10:46:10.405Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/vUGDuACi66Tta8Cf-mBYm_uP4Ds=/cloudfront-us-east-1.images.arcpublishing.com/norstella/EKWPP4SRXNFJ5KRD33XEBEE7MQ.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/hbw-insight/health/business/deals/japans-suntory-makes-major-otc-play-with-daiichi-sankyo-deal-LMBT5A4DT5HANN6LNWLWFKYCTM/</loc><lastmod>2026-04-15T10:19:50.815Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/vUGDuACi66Tta8Cf-mBYm_uP4Ds=/cloudfront-us-east-1.images.arcpublishing.com/norstella/EKWPP4SRXNFJ5KRD33XEBEE7MQ.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/generics-bulletin/products/generics/ofev-rivals-hit-us-as-five-firms-get-fda-nod-JKMCINNFH5B7BJNOFYP3R4CGMU/</loc><lastmod>2026-04-15T10:08:59.472Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/uMTq6tjXeJdAG94PhRtykXyQIRw=/cloudfront-us-east-1.images.arcpublishing.com/norstella/7MM3ZZBEDVGEFI2QPWWCCNCHSE.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/hbw-insight/leadership/interviews/serving-billions-not-just-selling-products-bayers-consumer-health-strategy-CYKUT6OSRBESFEEHPCWMUNJ5E4/</loc><lastmod>2026-04-15T08:51:58.153Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/XkV2aP8wqv5xqrmyavIIGuk3qSI=/cloudfront-us-east-1.images.arcpublishing.com/norstella/6DP77GHGH5DJHC75SVSIKTEGPI.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/scrip/leadership/interviews/alphamabs-bispecific-phase-iii-win-in-breast-cancer-lays-runway-for-take-off-W62ZI5XSDVCOFKM5EC22EKFUHQ/</loc><lastmod>2026-04-15T08:29:22.284Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/QByWLYYFLGqGlKoxCfQhv78uD0k=/cloudfront-us-east-1.images.arcpublishing.com/norstella/N7TOWQXANFKJXIT5B3BTKRDHBM.jpg</image:loc><image:caption><![CDATA[Alphamab Oncology's CEO talks about the firm's late-stage anti-HER2 bispecific antibody and ADC and rationales of developing the first-in-class ADCs. ]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/generics-bulletin/conferences/AAM/its-day-and-night-haruvi-on-how-the-aam-has-evolved-TYH3HIOGJFAFHBH6IG2VAPWY3I/</loc><lastmod>2026-04-15T07:11:02.859Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/DAofbbCF6Zf82OSvOnjDp0w1Qfs=/cloudfront-us-east-1.images.arcpublishing.com/norstella/YJ72AXDW5FA4HMSB24P5BSK5EI.jpg</image:loc><image:caption><![CDATA[Keren Haruvi is the outgoing chair of the AAM]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/generics-bulletin/leadership/interviews/its-not-a-question-of-if-its-a-question-of-when-sandozs-haruvi-on-us-biosimilar-1-ambitions-YK3SDEQHKJHEHHRT72IPBD3RW4/</loc><lastmod>2026-04-15T07:10:50.581Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/q7RDWPf1hWMSJPjTo9_-GWO-xWI=/cloudfront-us-east-1.images.arcpublishing.com/norstella/M4J5YTT5WZCXRKV4VT7VYKHLDM.jpg</image:loc><image:caption><![CDATA[Sandoz is aiming to be number one in US biosimilars]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/business/deals/licensing-deal-for-progeria-drug-could-benefit-zydus-in-more-ways-than-one-KJAJUVK5KNBHTFKMVJNEDPF5OY/</loc><lastmod>2026-04-15T06:36:54.813Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/4hXgMZpSyo9Pz88P9ognMddxeM4=/cloudfront-us-east-1.images.arcpublishing.com/norstella/UMT2HXEMVZF4BD55AOE2RE6WUE.jpg</image:loc><image:caption><![CDATA[Zydus Is Likely To Have Two Progeria Drugs]]></image:caption></image:image></url><url><loc>https://insights.citeline.com/scrip/business/earnings/az-optimistic-on-japan-prospects-despite-pricing-loe-challenges-DKBVZ6JYTRCDHKA2U33Y7Z7AMI/</loc><lastmod>2026-04-15T05:51:52.085Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/ooWRRRuAysoqCsb99POftf5loLY=/cloudfront-us-east-1.images.arcpublishing.com/norstella/MX66A5YKL5BDHLPGBXBTQC22SA.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/hbw-insight/beauty/policy-and-regulation/compliance/eu-beauty-industry-facing-first-compliance-deadline-for-allergen-labeling-CE43ZMOVFJH2PGHP4LLU7SGOE4/</loc><lastmod>2026-04-15T02:59:45.727Z</lastmod><changefreq>always</changefreq><priority>0.5</priority><image:image><image:loc>https://insights.citeline.com/resizer/wogj0Aq3_swGGO8qQgwKiaUT5jg=/cloudfront-us-east-1.images.arcpublishing.com/norstella/O5YBXIBY7ZHX7G4GRMVK74JW6U.jpg</image:loc></image:image></url><url><loc>https://insights.citeline.com/companies/liaoning-medical-of-diagnosis-and-treatment-technology-rd-center-co-ltd</loc><lastmod>2026-04-15T00:09:01.143Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/national-cerebral-and-cardiovascular-center</loc><lastmod>2026-04-15T00:08:55.26Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/hesperos-inc</loc><lastmod>2026-04-15T00:08:49.191Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/icura-diagnostics-inc</loc><lastmod>2026-04-15T00:08:43.058Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/guangzhou-manjing-biomedicine-technology-co-ltd</loc><lastmod>2026-04-15T00:08:37.165Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/alderley-analytical</loc><lastmod>2026-04-15T00:08:31.02Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/melius-microbiomics-pty-ltd</loc><lastmod>2026-04-15T00:08:24.884Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/chemify</loc><lastmod>2026-04-15T00:08:19.016Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/cook-myosite</loc><lastmod>2026-04-15T00:08:12.839Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/shanghai-sinobay-biotechnology-co-ltd</loc><lastmod>2026-04-15T00:08:07.001Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/sugentech-inc</loc><lastmod>2026-04-15T00:08:00.949Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/unc-lineberger</loc><lastmod>2026-04-15T00:07:54.793Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/steincares</loc><lastmod>2026-04-15T00:07:49.003Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/proton-intelligence-inc</loc><lastmod>2026-04-15T00:07:42.685Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/polku-therapeutics</loc><lastmod>2026-04-15T00:07:36.781Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/sonavex-inc</loc><lastmod>2026-04-15T00:07:30.792Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/rnatics</loc><lastmod>2026-04-15T00:07:25.257Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/spima-therapeutics</loc><lastmod>2026-04-15T00:07:18.767Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/stemmedical-as</loc><lastmod>2026-04-15T00:07:12.846Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/telomir-pharmaceuticals-inc</loc><lastmod>2026-04-15T00:07:06.584Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/klotho-neurosciences-inc</loc><lastmod>2026-04-15T00:07:00.682Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/rize-oncology-inc</loc><lastmod>2026-04-15T00:06:54.326Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/sonendo-inc</loc><lastmod>2026-04-15T00:06:48.368Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/poolbeg-pharma-plc</loc><lastmod>2026-04-15T00:06:42.304Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/queens-university-belfast</loc><lastmod>2026-04-15T00:06:36.326Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/ethzilla-corporation</loc><lastmod>2026-04-15T00:06:30.135Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/sentynl-therapeutics-inc</loc><lastmod>2026-04-15T00:06:24.448Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/swixx-biopharma-ag</loc><lastmod>2026-04-15T00:06:18.563Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/university-of-florida</loc><lastmod>2026-04-15T00:06:12.173Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/staurus-pharma</loc><lastmod>2026-04-15T00:06:06.443Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/sunrise-medical-inc</loc><lastmod>2026-04-15T00:06:00.158Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/augmedics</loc><lastmod>2026-04-15T00:05:54.043Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/repair-biotechnologies-inc</loc><lastmod>2026-04-15T00:05:48.075Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/earle-a-chiles-research-institute</loc><lastmod>2026-04-15T00:05:42.063Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/micromedic-technologies-ltd</loc><lastmod>2026-04-15T00:05:36.157Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/childrens-hospital-colorado</loc><lastmod>2026-04-15T00:05:30.056Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/university-of-california-berkeley</loc><lastmod>2026-04-15T00:05:24.475Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/university-of-maryland</loc><lastmod>2026-04-15T00:05:17.99Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/university-of-miami</loc><lastmod>2026-04-15T00:05:11.828Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/vivosim-labs-inc</loc><lastmod>2026-04-15T00:05:06.278Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/university-of-alberta</loc><lastmod>2026-04-15T00:04:59.939Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/university-of-birmingham</loc><lastmod>2026-04-15T00:04:53.786Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/sunny-pharmtech-inc</loc><lastmod>2026-04-15T00:04:47.869Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/stayble-therapeutics-ab</loc><lastmod>2026-04-15T00:04:41.719Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/protara-therapeutics-inc</loc><lastmod>2026-04-15T00:04:36.064Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/inexia-limited</loc><lastmod>2026-04-15T00:04:23.616Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/vaso-corporation</loc><lastmod>2026-04-15T00:04:17.682Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/envveno-medical-corporation</loc><lastmod>2026-04-15T00:04:11.602Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/mitsubishi-corporation</loc><lastmod>2026-04-15T00:04:05.797Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/pressure-biosciences-inc</loc><lastmod>2026-04-15T00:03:56.467Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/stereotaxis-inc</loc><lastmod>2026-04-15T00:03:44.227Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/sonoma-pharmaceuticals-inc</loc><lastmod>2026-04-15T00:03:32.515Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/starpharma-holdings-limited</loc><lastmod>2026-04-15T00:03:20.323Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/the-cooper-companies-inc</loc><lastmod>2026-04-15T00:03:08.678Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/aethlon-medical-inc</loc><lastmod>2026-04-15T00:02:57.061Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/imunon-inc</loc><lastmod>2026-04-15T00:02:32.27Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/oncoinvent-asa</loc><lastmod>2026-04-15T00:02:20.35Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/enzo-biochem-inc</loc><lastmod>2026-04-15T00:02:08.137Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/akari-therapeutics-plc</loc><lastmod>2026-04-15T00:01:56.123Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/citius-pharmaceuticals-inc</loc><lastmod>2026-04-15T00:01:43.998Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/daiichi-sankyo-co-ltd</loc><lastmod>2026-04-15T00:01:32.42Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/rigel-pharmaceuticals-inc</loc><lastmod>2026-04-15T00:01:20.256Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url><url><loc>https://insights.citeline.com/companies/enzon-pharmaceuticals-inc</loc><lastmod>2026-04-15T00:01:08.905Z</lastmod><changefreq>always</changefreq><priority>0.5</priority></url></urlset>